In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.
GBI Research analysis showed that the global bone and joint infections market was estimated at $0.7 billion in 2009, with a year-on-year growth rate of 6.4% between 2001 and 2009. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 8.1% between 2009 and 2016 to record a sales value of $1.2 billion. The patent expiry of two of the branded drugs by 2016 is expected to make way for the entry of generics.
Many of the major pharmaceutical companies such as GlaxoSmithKline, Hoffman-La Roche, Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira, Leo pharma A/S, App pharmaceuticals and Abbott are either entering or expanding into the market. They are collaborating with or acquiring small and medium-sized enterprises (SME) biotechnology companies. The main factor that is driving the big pharmaceutical companies towards the bone and joint infections therapeutics market is the increasing market for infectious diseases mainly indications related to infections caused due to staphylococcus species. As staphylococcus aureus is one of the major causative organisms for infectious diseases. Bone and joint infections is one of the most common infectious diseases.
- Data and analysis on the bone and joint infections market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the bone and joint infections market from 2001 to 2009, with forecasts to 2016.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy and treatment usage patterns such as disease population, treatment seeking population, diagno
Copyright©2010 PR Newswire.
All rights reserved